Pharming licenses North American Rhucin rights to Santarus
This article was originally published in Scrip
Executive Summary
Pharming has helped to ease concerns over its future by selling the North American commercialisation rights to its lead product Rhucin (recombinant human C1 inhibitor) to Santarus for $15 million up front.